このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

2020年3月13日 更新者:University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

調査の概要

状態

わからない

詳細な説明

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

研究の種類

介入

入学 (予想される)

50

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Clermont-Ferrand、フランス、63000
        • CHU de Clermont-Ferrand

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年~16年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

介入なし:Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
cardiac ectopic fat deposits
時間枠:Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
時間枠:Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
時間枠:Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
時間枠:Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
時間枠:Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
時間枠:Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
時間枠:Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
時間枠:Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
時間枠:Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
時間枠:Day 0
left myocardial regional function (MRI)
Day 0

二次結果の測定

結果測定
メジャーの説明
時間枠
macrovascularisation
時間枠:Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
時間枠:Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
時間枠:Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
時間枠:Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
時間枠:Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
時間枠:Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
時間枠:Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
時間枠:Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
時間枠:Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
時間枠:Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
時間枠:Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
時間枠:Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
時間枠:Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
時間枠:Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
時間枠:Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
時間枠:Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
時間枠:Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
時間枠:Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
時間枠:month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
時間枠:Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
時間枠:Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
時間枠:Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
時間枠:Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
時間枠:Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
時間枠:Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
時間枠:month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
時間枠:Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
時間枠:Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
時間枠:Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
時間枠:Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
時間枠:Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
時間枠:Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
時間枠:Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
時間枠:Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
時間枠:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
時間枠:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
時間枠:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
時間枠:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
時間枠:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
時間枠:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
時間枠:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
時間枠:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
時間枠:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
時間枠:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
時間枠:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
時間枠:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
時間枠:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
時間枠:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
時間枠:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
時間枠:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
時間枠:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
時間枠:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
時間枠:Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
時間枠:Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
時間枠:Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
時間枠:Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
時間枠:Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
時間枠:Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
時間枠:day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
時間枠:Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
時間枠:Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
時間枠:Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
時間枠:day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
時間枠:Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
時間枠:day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
時間枠:Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
時間枠:Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
時間枠:Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
時間枠:Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
時間枠:Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
時間枠:Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
時間枠:Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
時間枠:Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
時間枠:Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
時間枠:Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
時間枠:Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
時間枠:Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
時間枠:Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
時間枠:Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
時間枠:Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
時間枠:Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
時間枠:Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
時間枠:Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
時間枠:Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
時間枠:Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
時間枠:Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
時間枠:Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
時間枠:Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
時間枠:Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
時間枠:Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
時間枠:Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
時間枠:Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
時間枠:Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
時間枠:Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
時間枠:day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
時間枠:Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
時間枠:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
時間枠:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
時間枠:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
時間枠:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
時間枠:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
時間枠:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
時間枠:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
時間枠:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
時間枠:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
時間枠:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
時間枠:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
時間枠:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
時間枠:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
時間枠:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
時間枠:day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
時間枠:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
時間枠:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
時間枠:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
時間枠:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
時間枠:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
時間枠:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
時間枠:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
時間枠:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
時間枠:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
時間枠:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
時間枠:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
時間枠:Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
時間枠:Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
時間枠:Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
時間枠:Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
時間枠:Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
時間枠:Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
時間枠:Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
時間枠:Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
時間枠:Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
時間枠:Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
時間枠:Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
時間枠:Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
時間枠:Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
時間枠:Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
時間枠:Day 0
measure of weight in kilograms
Day 0
weight
時間枠:Month 3
measure of weight in kilograms
Month 3
waist circumference
時間枠:Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
時間枠:Month 3
measure of waist circumference in centimetres
Month 3

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (予想される)

2020年9月1日

一次修了 (予想される)

2021年6月1日

研究の完了 (予想される)

2021年6月1日

試験登録日

最初に提出

2020年2月10日

QC基準を満たした最初の提出物

2020年3月13日

最初の投稿 (実際)

2020年3月17日

学習記録の更新

投稿された最後の更新 (実際)

2020年3月17日

QC基準を満たした最後の更新が送信されました

2020年3月13日

最終確認日

2020年2月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (その他の識別子:ANSM)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

3
購読する